KDM6B and esophageal squamous cell carcinoma: Finally, KDM3A and KDM6B decreased expression was accomplished in CAM tumors treated with IOX1 inhibitor (Fig. 6e and Supplementary Fig. S4), although only H3K9me2 was significantly increased in target marks (Fig. 6e and Supplementary Fig. S4), supporting in vitro findings, and thus, indicating KDM3A as a key targetable molecule to radiosensitize hypoxic ESCC.